Fungal infections in solid organ transplant patients

Surgical Infections

Volumn 4, Issue 3, 2003, Pages 263-271

  Hagerty, Jennifer A ^a,b   Ortiz, Jorge ^a,b   Reich, David ^a,b   Manzarbeitia, Cosme ^a,b  

^a Albert Einstein Medical Center ^*

^b ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CALCINEURIN INHIBITOR; CASPOFUNGIN; CLOTRIMAZOLE; COTRIMOXAZOLE; CYCLOSPORIN; DACLIZUMAB; DAPSONE; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; OKT 3; PENTAMIDINE; RAPAMYCIN; TACROLIMUS; VORICONAZOLE;

ASPERGILLOSIS; CANDIDIASIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RISK; INTESTINE GRAFT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MULTIPLE ORGAN FAILURE; MYCOSIS; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PNEUMOCYSTIS CARINII; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

EID: 0242490750     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/109629603322419607     Document Type: Review

References (66)

1. Sabesin SM, Williams JW. Current status of liver transplantation. Hosp Pract 1987;22:75-86.
2. Patterson JE. Epidemiology of fungal infections in solid organ transplant patients. Transplant Infect Dis 1999;1:229-236.
3. Castaldo P, Stratta RJ, Wood RP, et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg 1991;126:149-156.
4. Kusne S, Dummer JS, Singh N, et al. Infections after liver transplantation: An analysis of 101 consecutive cases. Medicine 1988;67:132-143.
5. Paya CV, Hermans PE, Washington JA II, et al. Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clin Proc 1989;40:347-353.
6. Wajszczuk CP, Dummer JS, Ho M, et al. Fungal infections in liver transplant recipients. Transplantation 1985;40:347-353.
7. Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994;170: 644-652.
8. Paya CV. Fungal infections in solid organ transplantation. Clin Infect Dis 1993;16:677-688.
9. Nieto-Rodriguez, JA, Kusne S, Manez R, et al. Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. Ann Surg 1996;223:71-97.
10. Patel R. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996;62:926-934.
11. Fishman J, Rubin RH. Fungal infections in the organ transplant recipient. Infect Dis Clin Practice 1998; 7:S42-S48.
12. Singh N. The current management of infectious diseases in the liver transplant recipient. Clin Liver Dis 2000;4.
13. Walsh TJ, Groll AH. Emerging fungal pathogens: Evolving challenges to immunocompromised patients for the twenty-first century. Transplant Infect Dis 1999;1:247-261.
14. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine 1999;78:123-138.
15. Singh N. Fungal infections in solid organ transplant patients. Presented at the Focus on Fungal Infections 8, Orlando, Florida, 1998.
16. Kanj SS, Welty-Wolf K, Madden J, et al. Fungal infections in lung and heart-lung transplant recipients. Medicine (Baltimore) 1996;75:142-156.
17. Brooks RG, Hofflin JM, Jamieson SW, et al. Infectious complications in heart-lung transplant recipients. Am J Med 1985;79:412-422.
18. Dauber JH, Paradis IL, Dummer JS. Infectious complications in pulmonary allograft recipients. Clin Chest Med 1990;11:291-308.
19. Dummer JS, Montero CG, Griffith BP, et al. Infections in heart-lung transplant recipients. Transplantation 1986;41:725-729.
20. Hibberd PL, Rubin RH. Clinical aspects of fungal infection in organ transplant recipients. Clin Infect Dis 1994;19:S33-S40.
21. Guillemain R, Lavarde V, Armein C, et al. Invasive aspergillosis after transplantation. Transplant Proc 1995;27:1307-1309.
22. Horvath J, Dummer S, Loyd J, et al. Infection in the transplanted and native lung after single lung transplantation. Chest 1993;104:681-685.
23. Kramer MR, Marshall SE, Starnes VA, et al. Infectious complications in heart-lung transplantation. Arch Intern Med 1993;153:2010-2016.
24. Patel R, Paya C. Infections in solid-organ transplant recipients. Clin Microbial Rev 1997;10:86-124.
25. Palmer SM, Alexander BD, Sanders LL, et al. Significance of blood stream infection after lung transplantation: analysis in 176 consecutive patients. Transplantation 2000;69:2360-2366.
26. Shererz RJ, Belani A, Kramer BS, et al. Impact of air filtration on nosocomial aspergillus infections: Unique risk of bone marrow transplant recipients. Am J Med 1987;83:709-718.
27. Kennedy MS, Deeg HJ, Siegel M, et al. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation 1983;35:211-215.
28. Levine MS, Shviner RB, Waters PF, et al. Analysis of antifungal prophylaxis in lung transplantation. Am J Respir Crit Care Med 1995;151:A460 (abstr).
29. Tollemar J, Hockerstedt K, Ericzon BG, et al. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. Transplantation 1995;59:45-50.
30. Nadeem I, Yeldani V, Sherdan P, et al. Efficacy of itraconazole prophylaxis for aspergillosis in lung transplant recipients. Presented at the Infectious Diseases Society of America Annual Meeting, Orlando, Florida, 1994.
31. Peters J, Levine SM, Anzueto A, et al. The use of itraconazole in single lung transplant patients. Am J Respir Crit Care Med 1995;151:A460 (abstr).
32. Kramer MR, Marshall SE, Denning DW, et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients with fungal disease. Ann Intern Med 1990;113:327-329.
33. Paterson DL, Singh N. Interactions between tacrolimus and antimicrobial agents, Clin Infect Dis 1997; 25:1430-1440.
34. Chugh KS, Sakhuja V, Jain S, et al. Fungal infections in renal allograft recipients. Transplant Proc 1992;24: 1940.
35. Chugh KS, Sakhuja V, Jain S, et al. High mortality in systemic fungal infections following renal transplantation in third-world countries. Nephrol Dialysis Transplant 1993;8:168.
36. Howard RJ, Simmons RL, Najarian JS. Fungal infections in renal transplant recipients. Ann Surg 1978;188:598.
37. Kumar MS, Cridge P, Molavi A, et al. Infectious complications in the first 100 days after renal transplantation. Transplant Proc 1995;27:2705.
38. Sia IG, Paya CV. Infectious complications following renal transplantation. Surg Clin North Am 1998;78 95-112.
39. Cohen J, Hopkin J, Kurtz J. Infectious complications after renal transplantation. Philadelphia: WB Saunders, 1988:533-573.
40. Rubin R. Infectious disease complications of renal transplantation. Kidney Int 1993;44:221.
41. Kong NC, Shaariah W, Morad Z, et al. Cryptococcus in a renal unit. Aust NZ J Med 1990;20:645.
42. Kapoor A, Flechner SM, O'Malley K, et al. Cryptococcal meningitis in renal transplant patients associated with environmental exposure. Transplant Infect Dis 1999;1:213-217.
43. Fisher J, Tuazon CU, Geelhoed GW. Mucormycosis in transplant patients. Am Surg 1980;46:315.
44. Masur H, Cheigh JS, Stuberbord WT. Infection following renal transplantation: A changing pattern. Rev Infect Dis 1982;4:1208.
45. Tollemar J. Fungal infections in solid organ transplant recipients. In: Bowden RA, Ljungman P, Paya CV, eds. Transplant Infections. Philadelphia: Lippincott-Raven, 1998:339-349.
46. Benedetti E. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. J Am Coll Surg 1996;183:307-316.
47. Humar A, Kandaswamy R, Granger D, et al. Decreased surgical risks of pancreas transplantation in the modern era. Ann Surg 2000;231(2).
48. Stratta RJ. Ganciclovir/acyclovir and fluconazole prophylaxis after simultaneous kidney-pancreas transplantation. Transplant Proc 1998;30:262.
49. Mazariegos GV, Reyes J. In pediatric organ transplantation. Pediatr Rev 1999;20:363-375.
50. Langas AN, Shaw BW, Antonson DL. Preliminary experience with intestinal transplantation in infants and children. Pediatrics 1996;97:443-448.
51. Alexander BD, Tapson VF. Infectious complications of lung transplantation. Transplant Infect Dis 2001;3: 128-137.
52. Patel R. Infections in recipients of kidney transplants. Infect Dis Clin North Am 2001;15:901-952.
53. Kramer MR, Stoehr C, Lewiston NJ, et al. Trimethoprim-sulfamethoxazole prophylaxis for Pneumocystis carinii infections in heart-lung and lung transplantation - How effective and how long? J Heart Lung Transpl 1996;15:881-887.
54. Tiphine M, Letscher-Bru, Herbrecht R. Amphotericin B and its new formulations: Pharmacologic characteristics, clinical efficacy, and tolerability. Transplant Infect Dis 1999;1:273-283.
55. Slain D. Intravenous itraconazole. Ann Pharmacother 2001;35:720-729.
56. Strahilevitz J, Sugar AM, Engelhard D. Fluconazole in transplant recipients: options and limitations. Transplant Infect Dis 2001;2:62-71.
57. Patterson TF. Editorial response: Approaches to the therapy of invasive mycoses - The role of amphotericin B. Clin Infect Dis 1998;26:339-340.
58. Bachmann SP, Perea S, Kirkpatrick WR, et al. In vitro activity of CANCIDAS against Candida albicans clinical isolates displaying different mechanisms of azole resistance. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 2000.
59. Antiviral Drugs Advisory Committee: Briefing Document for Voriconazole (oral and intravenous formulations). New York; Pfizer, 2002.
60. Eason JD, Loss GE, Blazek J, et al. Steriod-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transplant 2001;7:693-697.
61. Emre S, Gondolesi G, Polat K, et al. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transplant 2001;7:220-225.
62. Trotter JF, Wachs M, Bak T, et al. Liver transplantation using sirolimus and minimal corticosteroids (3 day taper). Liver Transplant 2001;7:343-351.
63. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;131:729-737.
64. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998;11:382-402.
65. Coleman DC, Rinaldi MG, Haynes KA, et al. Importance of Candida species other than Candida albicans as opportunistic pathogens. Med Mycol 1998;36:156-165.
66. Rangel-Frausto MS, Wiblin T, Blumberg H, et al. National epidemiology of mycoses survey: Variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999;29:253-258.